Related Experiment Video

Updated: Jul 5, 2026

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
13:08

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate

Published on: September 9, 2011

The effects of zoledronic acid on serum lipids in multiple myeloma patients

Alessandro Gozzetti1, Luigi Gennari, Daniela Merlotti

  • 1Division of Hematology and Transplants, Policlinico "Santa Maria Le Scotte", University of Siena, Siena 53100, Italy. gozzetti@unisi.it

Calcified Tissue International
|April 18, 2008
PubMed

Insights

Zoledronic acid (ZA), a nitrogen-containing bisphosphonate, significantly reduced total cholesterol and LDL cholesterol in patients with smoldering myeloma, improving cardiovascular risk markers.

Area of Science:

  • Pharmacology
  • Oncology
  • Cardiovascular Medicine

Background:

  • Nitrogen-containing bisphosphonates (N-BPs) are used to treat tumor-associated osteolysis by inhibiting bone resorption.
  • The precise mechanism of N-BPs is not fully understood, but they may inhibit squalene synthase or farnesyl pyrophosphate synthase.
  • Zoledronic acid (ZA) is a novel N-BP with demonstrated antitumor activity.

Purpose of the Study:

  • To investigate the effects of zoledronic acid (ZA) on serum lipid profiles in patients with smoldering myeloma.
  • To assess changes in cardiovascular risk indexes following ZA administration.

Main Methods:

  • A study involving 26 patients diagnosed with smoldering myeloma.
  • Sixteen patients received intravenous ZA (4 mg) at baseline and at months 1, 2, 4, and 6.
  • Ten patients served as a control group; serum lipids (TC, TGs, HDL-C, LDL-C) and CTX were measured at baseline and at 1, 3, and 6 months.

Main Results:

  • Zoledronic acid treatment led to a significant, progressive reduction in total cholesterol (TC), with a maximum decrease of 13% at 6 months.
  • LDL cholesterol (LDL-C) decreased by 21% at 6 months; no significant changes were observed in HDL-C or triglycerides (TGs).
  • Cardiovascular risk indexes improved: the TC/HDL-C ratio decreased by 17%, and the HDL-C/LDL-C ratio increased by 36%.

Conclusions:

  • Intravenous administration of zoledronic acid at high doses in patients with smoldering myeloma can modify lipid profiles.
  • ZA treatment appears to improve the atherosclerotic risk index, suggesting a potential benefit beyond bone resorption inhibition.
  • The observed effects on lipid profiles suggest a cumulative impact of ZA, warranting further investigation into its pleiotropic effects.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...